The effects of oral iron supplementation on the progression of anemia and renal dysfunction in patients with chronic kidney disease

Clinical Nephrology

Volumn 75, Issue 5, 2011, Pages 472-479

  Kim, S M ^a,b   Lee, C H ^b,c   Oh, Y K ^b,c   Joo, K W ^b   Kim, Y S ^b   Kim, S ^b   Lim, C S ^b,c  

^a Chungbuk National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

Author keywords

Anemia; Chronic kidney disease; Oral iron; Renal disease progression

Indexed keywords

FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; AGED; CHRONIC DISEASE; DIET SUPPLEMENTATION; KIDNEY DISEASE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; CHRONIC DISEASE; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79958743740     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75472     Document Type: Article

References (25)

1. Vaziri ND. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol. 2008; 4: 436-445.
2. Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP, Valderrabano F. Predialysis survey on anemia management: Patient referral. Am J Kidney Dis. 2003; 41: 49-61.
3. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003; 18: 89-100.
4. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis. 2007; 49: 736-743.
5. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001; 55: 212-219.
6. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006; 26: 445-454.
7. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a commoncause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006; 19: 161-167.
8. Silverberg DS, Iaina A, PeerG, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.AmJ Kidney Dis. 1996; 27: 234-238.
9. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006; 21: 120-124.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999; 130: 461-470.
11. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002; 13: 2783-2786.
12. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19: 1-47.
13. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47: 1-146.
14. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002; 13: 504-510.
15. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M, Mircescu G. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010; 55: 639-647.
16. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003; 51: 170-174.
17. Charytan C, QunibiW, Bailie GR, Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to toral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100: 55-62.
18. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19: 1599-1605.
19. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephron Dial Transplant. 2001; 16: 967-974.
20. Van wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; for the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005; 68: 2846-2856.
21. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008; 52:897-906.
22. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004; 65: 1802-1809.
23. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int. 2004; 66: 144-156.
24. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106: 2212-2217.
25. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidativeDNAdamage in peripheral blood lymphocytes in chronic hemodialysis patients. JAmSoc Nephrol. 2008; 19: 1817-1826.